



FOR IMMEDIATE RELEASE

**Patients Enrollment completed in Clinical Study on Propiverine Hydrochloride
Modified Release Capsules for treatment of Urinary Incontinence**

Hong Kong, April 12, 2011—Lee's Pharmaceutical Holdings Limited (Main Broad Stock: 0950: Website: www.leespharm.com) today announced that the Group has achieved its enrollment target for a clinical trial conducted in China on Apogepha's original product, **Mictonorm® XL** (Propiverine Hydrochloride 30mg Modified-Release Capsule), to evaluate the effectiveness and safety for treatment in Chinese patients with urinary incontinence (overactive bladder).

This is a multi-centers, randomized, double-blind and double-dummy clinical trial, evaluating the safety and efficacy of Mictonorm® XL for the treatment of overactive bladder with Tolterodine Extended-release tablet as active parallel control. The trial was conducted in over 12 clinical centers located in Beijing, Shanghai, Guangzhou, Hebei etc; and led by Beijing Chao Yang Hospital of Capital Medical University. In January 2010, the Group initiated enrollment, and has successfully reached the target enrollment of 325 patients to date. The primary endpoint of the trial is to compare the mean micturition frequency within 24h prior to medication and 8 weeks after medication. Secondary endpoints include the mean incontinence frequency, mean micturition, the change of mean micturition volume, duration of response and quality of life.

"We're very pleased to see Mictonorm® XL study reached its enrollment target on schedule. We want to thank our clinical investigators, study coordinators and patients who participated in our trial. We would also like to thank our clinical development team for their diligence and efforts in managing this study, and Apogepha for its enthusiastic support and tremendous commitment", said Dr. Benjamin Li, the Chief Executive Officer of the Company.

Mictonorm® XL is for oral use containing Propiverine Hydrochloride (propiverine) as active ingredient, which is a type of medicine called an anticholinergic or antimuscarinic muscle relaxant. Propiverine is one of the most frequently prescribed drugs for the treatment of urinary incontinence and overactive bladder, as well as urgency and frequency in unstable bladder conditions. It works by relaxing the involuntary muscle contractions of the bladder muscle by blocking receptors called cholinergic or muscarinic receptors that are found on the surface of the muscle cells. Oxybutynin is the most widely used drug on the market for bladder instability. Propiverine as a newer agent available for the treatment of bladder instability was tolerated better than oxybutynin, especially with regard to dryness of the mouth.

"We will unblind the study in 8 weeks and have the study report ready by June 2011 for filing to the SFDA for Imported Drug License (IDL)".

FOR IMMEDIATE RELEASE

About Urinary Incontinence

Urinary incontinence is a common condition, particularly in women, the elderly and patients with neurological disease. It may cause considerable disruption to sufferers' quality of life yet many may be cured or significantly improved with appropriate treatment. Urge incontinence can mean that your bladder empties at any time even during sleep, also after drinking a small amount of water. Certain fluids and medications such as diuretics or emotional states as anxiety can worsen this condition. Some medical conditions, such as hyperthyroidism and uncontrolled diabetes, can also lead to or worsen urge incontinence.

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Leespharm focuses on several key therapeutic areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from 18 US, European and Japanese companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

About Apogepha

Apogepha Arzneimittel GmbH founded in Dresden, Germany in 1882, presents itself today as a highly competitive independent pharmaceutical company. APOGEPHA has focused its activities on marketing and sales of urologic medicine with a turnover share of more than 80% by now. Approvals for propiverine have been issued in Belgium, Croatia, Czech Republic, Egypt, Germany, Greece, Hong Kong, Indonesia, Ireland, Italy, Korea, Lebanon, Japan, Malaysia, Philippines, Portugal, Singapore, Slovakia, Slovenia, South Africa, Turkey, United Arab Emirates and United Kingdom. For more company information, please visit www.apogepha.com.

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com